Ligand Pharmaceuticals Incorporated - Common Stock · Transaction May 29, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
NASDAQ NMS - GLOBAL MARKET · LGND
-0.42% · -$1.21 · Vol 372.8K
Market closed · last close 4:00 PM ET · price as of 16:29:33 ET
Ligand Pharmaceuticals Inc
Pharmaceuticals
$283.49
Follow $LGND
One email when a member of Congress discloses a trade in it, with the official filing receipt linked.
Free. No account. Unsubscribe in one click.
Follow $LGND by emailVeridion Score
BETAMEDIUM CONF · 6 of 6 factors measuredFri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET · LGND
MethodologyLGND
Ligand Pharmaceuticals Inc
Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Middle range
Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.
Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
58/ 100
Veridion Score
Middle range · MEDIUM confidence · 6 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Start Sovereign · $25/mo →
Cancel anytime · or Reserve · $79/mo
Confidence: MEDIUM · 6 of 6 factors measured · Fri Sep 18 · last completed session · Markets closed · resumes Mon 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
SovereignWhy is LGND moving today?
Sovereign unlock connects news, insider activity, analyst moves, and live price action.
About Ligand Pharmaceuticals Inc
PHARMACEUTICAL PREPARATIONSListed since
1994
Employees
47
Country
US
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Key statistics
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Open
$285.63
Day high
$285.64
Day low
$280.49
Previous close
$284.70
52W high
$322.61
-12.13% from high
52W low
$166.76
75% of range
Market cap
$5.7B
P/E
37.95×
EPS
$7.47
Beta
0.48
Shares out
19.9M
Volume
372.8K
1.71× rel vol
Avg volume
218.5K
VWAP
$283.37
Price history computed in-house
1W
+1.01%
1M
-0.98%
3M
+1.45%
1Y
+70.26%
YTD
+49.94%
SMA 50 $291.70 · below
SMA 200 $236.01 · above
52W position 75%
LGND overview
Related filings and maps
Public disclosures
Congress activity in LGND
Official filing ↗
LGND · Transaction May 29, 2026 · Filed Jun 8, 2026 · $1,001 to $15,000
LGND · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
Ligand Pharmaceuticals Incorporated - Common Stock · Transaction Mar 3, 2026 · Filed Apr 7, 2026 · $1,001 to $15,000
LGND · Transaction Jan 15, 2026 · Filed Feb 13, 2026 · $1,001 to $15,000
Federal contracts
LGND contract awards, year to date.
Public federal awards linked to this ticker.
Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for LGND in this window.
Lobbying spend
LGND lobbying filings, year to date.
Registered lobbying filings matched to Ligand Pharmaceuticals Inc.
Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for LGND in this window.
Analyst ratings
Sovereign unlock shows live analyst consensus for LGND.
Options
Sovereign unlock shows live options positioning for LGND.